$CRMD

CorMedix Says Rezzayo Met Primary Endpoint in Study of Prevention of Invasive Fungal Diseases

CorMedix Therapeutics (CRMD) said Monday that a phase 3 trial evaluating Rezzayo for the prevention of invasive fungal diseases in stem cell transplant patients met its primary endpoint.The trial met the primary endpoint of 60.7% fungal-free survival at day 90 compared to 59.0% for the standard antimicrobial regimen, the company said.Rezzayo, or rezafungin for injection, was well tolerated with a safety profile showing a favorable benefit-risk profile for immunocompromised patients, CorMedix said.Shares of CorMedix were up 2.3% in Monday trading.Price: $7.67, Change: $+0.25, Percent Change: +3.37%